Back to Ovarian Cancer
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT01484015

NCT01484015
Completed Phase 1

Who may be able to join

Who might be able to join this trial:

  • Your blood has very low levels of infection-fighting white blood cells (called neutrophils), or your levels are expected to drop very low soon
  • You currently have a fever above 38.0°C (100.4°F)
  • You have received chemotherapy or a stem cell transplant to treat cancer or a blood/bone marrow condition called myelodysplastic syndrome (MDS)
  • You have been prescribed a specific antibiotic called cefepime, given through a drip at a dose of 2 grams every 8 hours

Who may not be able to join:

  • You have a known allergy to a group of antibiotics called cephalosporins (such as cephalexin or cefazolin)
  • Your kidneys are not working well enough (based on a blood test measuring kidney filtering ability) (confirm with trial site)
  • You are already taking other antibiotics that target a certain type of bacteria called gram-negative bacteria
  • You show signs that may suggest a serious body-wide infection called sepsis (confirm with trial site)
  • There are practical reasons why receiving a 3-hour drip/infusion would not be possible for you
  • Your cancer is a solid tumour (a lump or mass in an organ or tissue, rather than a blood or bone marrow cancer)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 1
Sponsor
Wake Forest University Health Sciences
Registry
clinicaltrials_gov
Start date
1 February 2011
Est. completion
1 June 2012

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Defervescence (without hypothermia)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov